Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.

Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M.

Leukemia. 2012 Mar;26(3):481-9. doi: 10.1038/leu.2011.225. Epub 2011 Aug 23.

2.

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.

Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J.

Mol Cancer Ther. 2008 Jan;7(1):110-20. doi: 10.1158/1535-7163.MCT-07-0482.

3.

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.

Chesney J.

Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):535-9. Review.

PMID:
16912547
4.

Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.

Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T.

Clin Cancer Res. 2005 Aug 15;11(16):5784-92.

5.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

6.

Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation.

Atsumi T, Nishio T, Niwa H, Takeuchi J, Bando H, Shimizu C, Yoshioka N, Bucala R, Koike T.

Diabetes. 2005 Dec;54(12):3349-57.

7.

6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro.

Yalcin A, Solakoglu TH, Ozcan SC, Guzel S, Peker S, Celikler S, Balaban BD, Sevinc E, Gurpinar Y, Chesney JA.

Biochem Biophys Res Commun. 2017 Mar 11;484(3):687-693. doi: 10.1016/j.bbrc.2017.01.178. Epub 2017 Feb 1.

PMID:
28161638
8.

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.

Kessler R, Bleichert F, Warnke JP, Eschrich K.

J Neurooncol. 2008 Feb;86(3):257-64. Epub 2007 Sep 6.

PMID:
17805487
9.

Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).

Imbert-Fernandez Y, Clem BF, O'Neal J, Kerr DA, Spaulding R, Lanceta L, Clem AL, Telang S, Chesney J.

J Biol Chem. 2014 Mar 28;289(13):9440-8. doi: 10.1074/jbc.M113.529990. Epub 2014 Feb 10.

10.

Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Aug 30;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. Epub 2012 Jul 26.

11.

PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1.

Lv Y, Zhang B, Zhai C, Qiu J, Zhang Y, Yao W, Zhang C.

Neurochem Int. 2015 Dec;91:26-33. doi: 10.1016/j.neuint.2015.10.006. Epub 2015 Oct 21.

PMID:
26498254
12.

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J.

J Transl Med. 2012 May 16;10:95. doi: 10.1186/1479-5876-10-95.

13.
14.

Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.

Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, Chesney J.

J Biol Chem. 2009 Sep 4;284(36):24223-32. doi: 10.1074/jbc.M109.016816. Epub 2009 May 27.

15.

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J.

Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14.

16.

Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells.

Novellasdemunt L, Obach M, Millán-Ariño L, Manzano A, Ventura F, Rosa JL, Jordan A, Navarro-Sabate A, Bartrons R.

Biochem J. 2012 Mar 1;442(2):345-56. doi: 10.1042/BJ20111418.

PMID:
22115192
17.

Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.

Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J.

Oncogene. 2006 Nov 23;25(55):7225-34. Epub 2006 May 22.

PMID:
16715124
18.

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.

Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S, Chesney J.

Cell Death Dis. 2014 Jul 17;5:e1337. doi: 10.1038/cddis.2014.292.

19.
20.

PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer.

Seo M, Lee YH.

J Mol Biol. 2014 Feb 20;426(4):830-42. doi: 10.1016/j.jmb.2013.11.021. Epub 2013 Dec 1.

Supplemental Content

Support Center